rgs-2 Antibody

Introduction to RGS2 Antibody

The RGS2 antibody is a specialized tool designed to detect and study the Regulator of G-protein Signaling 2 (RGS2), a critical protein involved in modulating G-protein-coupled receptor (GPCR) signaling pathways. RGS2 accelerates GTP hydrolysis by Gα subunits, terminating GPCR signals and influencing downstream cellular processes such as proliferation, differentiation, and apoptosis . Antibodies targeting RGS2 are widely used in research to investigate its roles in cardiovascular regulation, immune response, cancer biology, and metabolic disorders .

Cardiovascular Research

RGS2 antibodies have been pivotal in studying hypertension and cardiac fibrosis:

• Blood Pressure Regulation: Central overexpression of RGS2 in the paraventricular nucleus (PVN) reduced blood pressure and sympathetic outflow in hypertensive rats .

• Cardiac Fibrosis: RGS2 knockdown in cardiac fibroblasts exacerbated angiotensin II (ANG II)-induced collagen production and fibroblast proliferation .

Cancer Biology

RGS2 expression correlates with cancer prognosis and therapy resistance:

Immune Response

• Acute Lung Injury (ALI): RGS2-deficient macrophages exhibited elevated IFNγ levels, exacerbating lung inflammation. RGS2 antibody studies revealed its role in shielding Gαq-TLR4 interactions to suppress innate immune hyperactivation .

Translational Control

RGS2 inhibits mRNA translation by binding eukaryotic initiation factor 2Bε (eIF2Bε), independent of its GTPase-activating function. Hepatocytes from RGS2−/− mice showed 60% higher protein synthesis rates than wild-type cells .

Signaling Pathway Modulation

• Gαq Inhibition: RGS2 overexpression in the PVN attenuated ANG II-induced upregulation of Gαq and Gαs mRNA (p < 0.05) .

• STAT3 Regulation: RGS2 knockdown increased STAT3 expression, promoting tumor cell survival via BCL-2 upregulation .

Clinical and Therapeutic Implications

• Biomarker Potential: RGS2 expression levels in HGSOC tumors may serve as a prognostic marker for chemotherapy response .

• Therapeutic Target: Targeting RGS2-Gαq interactions in macrophages could resolve inflammatory lung injury .